Sildenafil (Revatio®) for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity

All Wales Medicines Strategy Group (AWMSG)

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
All Wales Medicines Strategy Group (AWMSG). Sildenafil (Revatio®) for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1010. 2010

Authors' conclusions
Sildenafil (Revatio®) is recommended, within its current licensed indication, as an option for use within NHS Wales for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity. AWMSG recommends that its use be restricted to a physician experienced in the treatment of PAH in association with a National Commissioning Group designated expert centre. AWMSG is of the opinion that sildenafil (Revatio®) is not suitable for shared care between primary and secondary care within NHS Wales.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Piperazines; Hypertension, Pulmonary; Antihypertensive Agents; Sulfones

Language Published
English

Country of organisation
Wales

English summary
An English language summary is available.

Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX Email: AWTTC@wales.nhs.uk

AccessionNumber
32012000385

Date abstract record published
08/08/2012